PDL BioPharma Inc

PDL BioPharma — Q1 2018 Earnings Presentation

15 slides from PDL BioPharma's earnings presentation, May 9, 2018

  1. Slide 1: First Quarter 2018 Financial Results Conference Call

    PDL First Quarter 2018 Financial Results Conference Call May 9, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua

  3. Slide 3: Building Value Through Investments

    Building Value Through Investments Q Focused on growth in order to continue value creation for shareholders. Q Pleased with our success in replacing the revenues from the expired Queen et al patents. = Strategic decisions have enabled income generating assets to fund PDL’s business of today. = 93 pe

  4. Slide 4: Building Value Through Investments: Book Value Per Share

    Building Value Through Investments PDL’s book value increased to $5.60 in the period ending March 31, 2018 PDL's Book Value Per Share RSASRSASRSASRS a SOSPREENNNNWWWWRER BMD Sa Prayspeyspeyshaysheushas ea Sepa3 Deca3 Mar14 sunt sepa Deca Maris sun-as Sepas Deets Mari6 sun-16 sepas Deca6 Mar17 sun-17

  5. Slide 5: Share Repurchase Programs

    Share Repurchase Programs Q Previous Program = In March 2017, PDL’s board authorized the repurchase of PDL common stock having an aggregate value of up to $30 million through March 2018. = Total repurchased under this program over 4 months was approximately 13.3 million shares at an average price of

  6. Slide 6: Noden Background

    Noden Background Q Noden Pharma = Platform upon which to build a pharmaceutical company. = PDL now owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. o Tekturna® and Tekturna HCT®, as they are known in the U.S., and Rasilez® and Rasilez HCT®

  7. Slide 7: Noden: Building Profitable Growth

    Noden: Building Profitable Growth a Reported revenues on the Noden products for Q118 of $18.3 million. = $10.5 million from US sales and $7.8 million from ROW. = 46 percent increase in productrevenues year over year. a EX-U.S. results reflect completed transfer of commercialization rights from Novar

  8. Slide 8: Tekturna & Tekturna HCT Prescriptions

    Tekturna & Tekturna HCT Prescriptions Weekly TRxs decline appears to be slowing Tekturna Prescription Data - All Strengths 6,000 = 5,000 4,000 Noden 3000 oe Increased promotion with 40 toed 2,000 reps = 1000 XX J 4/2017 2/s/2017 3/6/2017 4/6/2017 $/6/2017 6/6/2017 7/6/2017 8/s/2017 9/6/2017 10/6/201

  9. Slide 9: Tekturna: Executing Targeted Patient-Type Strategy

    Tekturna Executing Targeted Patient-Type Strategy ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD Estimated 6 million patients Estimated 3.3 million patients

  10. Slide 10: Continued Progress at LENSAR

    Continued Progress at LENSAR Q Achieved quarterly revenue of $5.0 million. Q LENSAR EBITDA was positive this quarter. Q Two systems sold in Q1 2018. Q Acquired laser business unit of Precision Eye Services (PES). = Consolidates LENSAR’s customer base for greater optimization, efficiency and speed to

  11. Slide 11: Royalty Investments

    "1 Royalty Investments Q Royalties relating to Depomed continue to exceed our expectations. = Cash returns of $325.4 million since inception through March 2018. = We received $16.9 million in cash royalties in Q1 2018. = Glumetza and its authorized generic account for bulk of returns. = Expect other

  12. Slide 12: First Quarter 2018 Income Statement

    First Quarter 2018 Income Statement ‘Three Months Ended March 31, (in thousands, except per share amounts) 2018 2017 Royalties from Queen et al. patents $2783 $14,156 Royalty rights - change in fair value 11,091 13,146 Interest revenue 749) 5,457 Product revenue, net 23,324 License and other 571 Tot

  13. Slide 13: First Quarter 2018 Non-GAAP Financials

    First Quarter 2018 Non- GAAP Financials Three Months Ended March 31, 2018 2017 GAAP net income attributed to PDL's shareholders as reported $1,602 $ 7,241 Adjustments Mark-to-market adustment to fair value assets 7,532 us Non-cash interest revenues (74) (75) Non-cash stock-based compensation expense

  14. Slide 14: First Quarter 2018 Financials

    First Quarter 2018 Financials Condensed consolidated balance sheet (unaudited) March 314, December 31, 2018 2017 Cash, cash equivalents and investments $ 405,078 $ 532,114 Total notes receivable $ 70,811 $ 70,737 Total royalty rights - at fair value $ 341,691 $ 349,223 Total assets $ 1,100,401 $ 1,2

  15. Slide 15: Question and Answer Session

    PDL Question and Answer Session

PDL BioPharma — Q1 2018 Earnings Presentation on 6ix